Rekvina Laboratories share news, announcements and annual reports
BSE: 526075Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 29 Oct 2026. Previous close ₹57.94.
29 Oct: open ₹57.94, high ₹57.94, low ₹55.05
- Under BSE's graded surveillance, stage 0, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹62 Cr4,235th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −139.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,401
Rekvina Laboratories has 399 announcements on record, routine notices left out; 2 in the 30 days to 30 Oct 2026, the latest on 27 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Rekvina Laboratories quarterly results
The board met on 13 Aug 2026 to consider quarterly results
Notice filed 3 Aug 2026
Rekvina Laboratories annual reports, presentations and earnings calls
The company's own documents, latest first.Rekvina Laboratories financials, year by year
Annual reports20
- Annual report, year to Mar 20263 Sep 2026
- Annual report, year to Mar 20251 Sep 2025
- Annual report, year to Mar 20242 Sep 2024
- Annual report, year to Mar 202211 Jul 2024
- Annual report, year to Mar 202111 Jul 2024
15 earlier reports
- Annual report, year to Mar 202011 Jul 2024
- Annual report, year to Mar 201911 Jul 2024
- Annual report, year to Mar 20236 Sep 2023
- Annual report, year to Mar 20181 Jan 2019
- Annual report, year to Mar 201727 Mar 2018
- Annual report, year to Mar 201621 Oct 2016
- Annual report, year to Mar 201510 Dec 2015
- Annual report, year to Mar 201410 Dec 2015
- Annual report, year to Mar 201312 Nov 2013
- Annual report, year to Mar 201227 Nov 2012
- Annual report, year to Mar 201125 Oct 2011
- Annual report, year to Mar 201025 Oct 2011
- Annual report, year to Mar 2000Filing day not known
- Annual report, year to Mar 1999Filing day not known
- Annual report, year to Mar 1997Filing day not known
Rekvina Laboratories share news and announcements
Newest first. Page 1 of 8.
Oct 2026
Sep 2026
29 Sep · Meeting
29 Sep · Meeting
23 Sep · Announcement under Regulation 30 (LODR)-Change in Registered Office Address
Aug 2026
14 Aug · Legal
13 Aug · Results
13 Aug · Results
12 Aug · Legal
Exchange has sought clarification from Rekvina Laboratories Ltd on August 12, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....12 Aug · Announcement under Regulation 30 (LODR)-Allotment
3 Aug · Board meeting
Meeting on 13 Aug 2026: quarterly results1 Aug · Announcement under Regulation 30 (LODR)-Open Offer - Updates
Jul 2026
31 Jul · Post Offer Advertisement
Jun 2026
30 Jun · Announcement under Regulation 30 (LODR)-Open Offer - Updates
30 Jun · Pre-Offer Advertisement & Corrigendum to Detailed Public Statement
25 Jun · Updates on Open Offer
25 Jun · Announcement under Regulation 30 (LODR)-Open Offer - Updates
24 Jun · Announcement under Regulation 30 (LODR)-Open Offer - Updates
23 Jun · Announcement under Regulation 30 (LODR)-Open Offer - Updates
May 2026
18 May · Board meeting
Meeting on 21 May 2026: audited results
Apr 2026
10 Apr · Meeting
10 Apr · Meeting
2 Apr · Announcement under Regulation 30 (LODR)-Open Offer - Updates
2 Apr · Draft Letter of Offer
Mar 2026
24 Mar · Announcement under Regulation 30 (LODR)-Open Offer - Updates
24 Mar · Detailed Public Statement
18 Mar · Meeting
17 Mar · Announcement under Regulation 30 (LODR)-Public Announcement-Open Offer
16 Mar · Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
16 Mar · Board meeting
11 Mar · Board meeting
Meeting on 16 Mar 2026: preferential issue of shares
Feb 2026
Jan 2026
29 Jan · Board meeting
Meeting on 6 Feb 2026: quarterly results
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 8 Oct 2026Board or managers changedup 1.92%+4.6 pts vs Nifty 500market median 0.0% · five sessions +20.3% (+21.1 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 24 Sep 2026Board or managers changeddown 1.98%−0.3 pts vs Nifty 500market median 0.0% · five sessions −5.9% (−2.1 pts vs Nifty 500) · volume 0.3× usual · The announcement
- 15 Sep 2026Board or managers changeddown 1.77%−0.1 pts vs Nifty 500market median 0.0% · five sessions −9.4% (−9.3 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 3 Sep 2026Board or managers changedup 1.99%+1.9 pts vs Nifty 500market median 0.0% · five sessions +10.3% (+11.5 pts vs Nifty 500) · volume 0.8× usual · The announcement